Halting the progression of heart failure: Finding the optimal combination therapy

Jan N. Basile, MD
Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC

Address: Jan N. Basile, MD, Ralph H. Johnson VA Medical Center, 109 Bee St, Charleston, SC 29403

Dr. Basile has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Jan N. Basile, MD
Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC

Address: Jan N. Basile, MD, Ralph H. Johnson VA Medical Center, 109 Bee St, Charleston, SC 29403

Dr. Basile has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Jan N. Basile, MD
Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC

Address: Jan N. Basile, MD, Ralph H. Johnson VA Medical Center, 109 Bee St, Charleston, SC 29403

Dr. Basile has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.